Lower riskDrug recall · FDA · Published February 14, 2019
McGuff Compounding Recall: DMPS Injection May Contain Particulates
McGuff Compounding Pharmacy Services recalls DMPS injection solution (50mg/mL 5mL) due to observed particulates in vials. This may pose a risk of injury if injected.
“McGuff Compounding Recall: DMPS Injection May Contain Particulates.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/39190-mcguff-compounding-recall-dmps-injection-may-contain-particulates. Based on FDA recall #D-0821-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0821-2020%22&limit=1).
The FDA announced on 2019-02-14 that McGuff Compounding Pharmacy Services, Inc. is recalling Dimercaptopropanesulfonate Sodium (DMPS) injection solution due to the presence of particulate matter in vials. The recall affects Lot #18J1081 distributed to patients in 19 states and DC.
How to tell if you have it
Brand: McGuff Compounding
Product: Dimercaptopropanesulfonate Sodium (DMPS), Aqueous injection solution, 50mg/mL 5 mL SDV, Rx only
Lot #: 18J1081
Expiration Date: 03/10/19
The hazard
Particulates were observed in vials released for dispensing. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show McGuff Compounding Pharmacy Services, Inc. has two other recalls on record since 2019-01-10. Other recent recalls of similar products include B. Braun Medical Lactated Ringer's Injection Recall (2026-08-12), Mallinckrodt Acthar Gel 5mL Vial Recall (2026-08-06), and American Regent Multrys IV injection recall (2026-07-24).
How to tell if you have this one
Check for the product name 'Dimercaptopropanesulfonate Sodium (DMPS), Aqueous injection solution, 50mg/mL 5 mL SDV' and the lot number 18J1081 with expiration date 03/10/19.
Brand
McGuff Compounding
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Look for the lot number 18J1081 and expiration date 03/10/19 on the vial label.
Where it went and when
Where it was distributed
Distributed in 18 states and D.C..
Listed by the agency
Not listed
FDA distribution: “Prescriptions filled for patients in the following states: AK, AZ, CA, CO, DC, FL, IN, MA, MT, NC, NJ, NY, OR, SC, TX, UT, VA, WA, and WI.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Alaska, Arizona, California, Colorado, District of Columbia, Florida, Indiana, Massachusetts, Montana, New Jersey, New York, North Carolina, Oregon, South Carolina, Texas, Utah, Virginia, Washington, Wisconsin.
Recall timeline
FDA terminated this recall 4.8 years after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0821-2020 (February 14, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0821-2020 to see it in context.
Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.